Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2019
ICER releases draft evidence report on acute migraine therapies
7 November 2019 - Public comment period on preliminary draft now open until 6 December 2019; requests to make oral comment ...
Posted by Michael Wonder on 05 Nov 2019
Obscure model puts a price on good health—and drives down drug costs
4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...
Posted by Michael Wonder on 01 Nov 2019
ICER report finds oral GLP-1 semaglutide, at estimated net price, less cost-effective than SGLT-2 competitor empagliflozin as add-on therapy for type 2 diabetes
1 November 2019 - Semaglutide as add-on therapy to metformin achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than ...
Posted by Michael Wonder on 30 Oct 2019
ICER posts draft scoping document for the assessment of treatments for non-alcoholic steatohepatitis
30 October 2019 - Document open to public comment until 20 November 20 2019. ...
Posted by Michael Wonder on 17 Oct 2019
ICER issues final report and policy recommendations regarding additive treatments for cardiovascular disease
17 October 2019 - Independent appraisal committee votes that rivaroxaban and icosapent ethyl improve patient health at prices that achieve ...
Posted by Michael Wonder on 17 Oct 2019
Some say a non-profit research group unfairly influences drug prices
16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...
Posted by Michael Wonder on 15 Oct 2019
Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...
Posted by Michael Wonder on 11 Oct 2019
ICER releases updated draft evidence report on rheumatoid arthritis therapies
11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...
Posted by Michael Wonder on 08 Oct 2019
Humira, Rituxan top list of U.S. costliest drug price increases
8 October 2019 - AbbVie Inc’s arthritis drug Humira and Roche's cancer drug Rituxan top the list of seven treatments ...
Posted by Michael Wonder on 08 Oct 2019
ICER identifies costliest US drug-price hikes that are not supported by new clinical evidence
8 October 2019 - In 2017 and 2018, out of nine identified drugs that had substantial price increases on top of ...
Posted by Michael Wonder on 01 Oct 2019
ICER posts draft scoping document for the assessment of treatments for cystic fibrosis
30 September 2019 - Document open to public comment until 21 October 2019. ...
Posted by Michael Wonder on 29 Sep 2019
ICER posts draft scoping document for the assessment of treatments for ulcerative colitis
27 September 2019 - Document open to public comment until 18 October 2019. ...
Posted by Michael Wonder on 26 Sep 2019
ICER releases draft evidence report on rheumatoid arthritis therapies
26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 11 Sep 2019
ICER releases draft evidence report on diabetes therapies
11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...